Clinical Trial Update: A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) [Phase 2]

View source ↗

Summary

Results from a Phase 2 study (CITADEL-202) of INCB050465 in relapsed or refractory diffuse large B-cell lymphoma have been completed and posted, detailing the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• INCB050465

Snippet

Sponsor: Incyte Corporation | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-04-24